Skip to main content
Medica logo

Medica — Investor Relations & Filings

Ticker · MDC ISIN · IT0005460149 LEI · 815600FE16FA9F3E2296 XMIL Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2024-03-25 Audit Report / Informat…
Country IT Italy
Listing XMIL MDC

About Medica

https://www.medica.it/

Medica S.p.A. is a company specializing in advanced purification technologies. Its core business is the development and production of products for blood purification, with applications in dialysis, Continuous Renal Replacement Therapy (CRRT), and apheresis. The company's medical product portfolio includes polysulfone membranes, dialysis filters, hemofilters, and blood lines. It has expanded its expertise into other medical fields such as cardiology, oncology surgery, organ transplantation, urology, and gastroenterology. Leveraging its filtration know-how, Medica also operates a water purification division that produces hollow fiber membranes. Additionally, the company offers turnkey solutions for the biomedical sector, providing vertically integrated services from research and development to manufacturing, industrial automation, and regulatory management.

Recent filings

Filing Released Lang Actions
Medica SpA - Approvazione risultati 2023
Audit Report / Information Classification · 98% confidence The document is titled 'Comunicato stampa' (Press Release) and announces the 'APPROVAZIONE DEL PROGETTO DI BILANCIO D'ESERCIZIO E DEL BILANCIO CONSOLIDATO PER L'ESERCIZIO CHIUSO AL 31 DICEMBRE 2023' (Approval of the draft financial statements and consolidated financial statements for the year ended December 31, 2023). It contains key summary financial data (Revenues, EBITDA, Net Result) for the full year 2023, management commentary, and details on the financial performance. This structure strongly indicates an Earnings Release (ER) which typically precedes the full Annual Report (10-K) or serves as the primary public disclosure of annual results in many jurisdictions. Since it is a comprehensive summary of the full year's results, it fits the 'Earnings Release' (ER) definition better than 'Interim Report' (IR) or 'Annual Report' (10-K) which is a specific SEC filing format not explicitly mentioned here. The document also mentions the convocation of the shareholders' meeting, but the primary focus is the financial results announcement. FY 2023
2024-03-25 Italian
Medica SpA - 510k authorization from the US FDA for the distribution of hemoconcentrators
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a 'Press Release' and announces a specific corporate event: receiving 510k authorization from the US FDA for product distribution. It contains key highlights, company profile information, and financial closing figures for the previous year (2022), but it is not a comprehensive regulatory filing like a 10-K, nor is it a full transcript or a detailed investor presentation. This type of announcement, focusing on a significant business development or regulatory milestone, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period, but since it's a specific business update, RNS is the most appropriate general category for non-standard announcements. Given the options, RNS serves as the best fit for a press release detailing a regulatory approval milestone that isn't a standard financial report.
2024-02-08 English
Medica SpA - autorizzazione 510k da FDA US alla commercializzazione di emoconcetratori
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Comunicato stampa" (Press Release) from MEDICA S.p.A. It announces a significant business event: receiving FDA 510(k) authorization for marketing hemoconcentrators in the US market. It includes commentary from the President and a brief profile of the company, concluding with 2022 financial highlights and contact information. This structure—a formal announcement of a material, non-financial event (regulatory approval) combined with brief financial context—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) and the core content is a specific business update rather than just a notice of publication, ER is a strong candidate if it were quarterly results, but here it is a specific regulatory milestone announcement. Given the options, this is a material corporate announcement that doesn't fit the specific financial report types (10-K, IR, MRQ). It is most closely aligned with an Earnings Release (ER) in function (announcing key period/business news) or RNS (general regulatory announcement). Since it contains financial figures (2022 results) but the main focus is the FDA approval, and it is a press release format, ER is often used for major news releases, but RNS is the best fit for a general, non-periodic regulatory/business update that isn't a full report or a management discussion. However, because it contains financial performance data for the previous year (2022 results), it shares characteristics with an ER, even if the primary news is regulatory. Given the options, and recognizing that this is a press release announcing a major operational/regulatory milestone, it is best classified as a general Regulatory Filing (RNS) as it is not a standard Earnings Release (which usually covers quarterly/annual performance summaries) or a Report Publication Announcement (RPA).
2024-02-08 Italian
Medica SpA - Preliminary consolidated Net Revenues and Net Financial Position as of 31 December 2023
Earnings Release Classification · 100% confidence The document is explicitly labeled as a 'Press Release' announcing 'Preliminary consolidated revenues for 2023' and preliminary net financial position data for the year ended December 31, 2023. It provides key financial highlights, divisional performance breakdowns, and commentary from the President. Crucially, it states that the data is preliminary and has not been audited, and mentions the future date (March 25, 2024) when the Board will approve the final financial statements. This structure—a high-level, immediate release of key figures before formal filing—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the Interim Report (IR), as it covers the full fiscal year but is preliminary. FY 2023
2024-02-06 English
Medica SpA - Ricavi Netti e Posizione Finanziaria Netta preconsuntivi consolidati al 31 dicembre 2023
Earnings Release Classification · 100% confidence The document is explicitly titled "Comunicato stampa" (Press Release) and presents preliminary consolidated financial results for the full year 2023 ("Fatturato consolidato preconsuntivo 2023"). It details key financial figures (revenue, net financial position) and provides commentary from management, comparing FY2023 preliminary data to FY2022 actuals. This structure—an initial, high-level announcement of period results before formal audit/board approval—aligns perfectly with the definition of an Earnings Release (ER). The text also mentions that the formal board approval for the final financial statements is scheduled for March 25, 2024, confirming this document is the preliminary announcement, not the full Annual Report (10-K) or the formal Audit Report (AR). FY 2023
2024-02-06 Italian
Medica SpA - Financial calendar 2024
Report Publication Announcement Classification · 95% confidence The document is explicitly titled 'Press Release' and its primary content is the 'FINANCIAL CALENDAR 2024', detailing future dates for Board meetings to approve preliminary results, draft financial statements, and the Ordinary Shareholders' Meeting. It also includes a brief company profile and historical 2022 financial highlights. This document is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a specific regulatory filing like a Director's Dealing (DIRS) or a Dividend Notice (DIV). Since it announces the schedule for future financial reporting events and provides a general update, it most closely aligns with an announcement regarding the publication or scheduling of reports, which falls under Report Publication Announcement (RPA). Given its short length and focus on announcing future reporting dates, RPA is the most appropriate classification, although RNS could be a secondary fallback if RPA was not available.
2024-01-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.